Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Published byGijs de Lange Modified over 5 years ago

Similar presentations

Presentation on theme: "Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial."— Presentation transcript:

1 Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)  Hiroyasu Kaneda, MD, Isamu Okamoto, MD, PhD, Hidetoshi Hayashi, MD, Hiroshige Yoshioka, MD, Masaki Miyazaki, MD, PhD, Shinzoh Kudoh, MD, PhD, Tatsuo Kimura, MD, PhD, Takamune Sugiura, MD, Toshiyuki Sawa, MD, PhD, Koji Takeda, MD, Yasuo Iwamoto, MD, PhD, Miyako Satouchi, MD, PhD, Kenji Akita, MD, PhD, Hiroshi Saito, MD, PhD, Isao Goto, MD, PhD, Kazuhiko Shibata, MD, PhD, Masahiro Fukuoka, MD, PhD, Kazuhiko Nakagawa, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 1, Pages (January 2010) DOI: /JTO.0b013e3181c07c6c Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier analysis of progression-free survival for all 61 treated patients. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181c07c6c) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan-Meier analysis of overall survival for all 61 treated patients. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181c07c6c) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,
Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR.

Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR.
Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe.

Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,
A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer  David R. Spigel,

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer  David R. Spigel,
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results  Makoto Nishio, Koichi.

P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results  Makoto Nishio, Koichi.
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Similar presentations

Ads by Google